| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 6 | 2020 | 332 | 1.260 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2020 | 16 | 0.710 |
Why?
|
| Colorectal Neoplasms | 8 | 2021 | 561 | 0.710 |
Why?
|
| Stomach Neoplasms | 5 | 2020 | 64 | 0.660 |
Why?
|
| Adenocarcinoma | 10 | 2017 | 475 | 0.620 |
Why?
|
| Pancreatic Diseases | 1 | 2015 | 66 | 0.510 |
Why?
|
| Pancreatitis, Chronic | 6 | 2007 | 168 | 0.370 |
Why?
|
| Celiac Disease | 2 | 2003 | 17 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2020 | 46 | 0.340 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 508 | 0.330 |
Why?
|
| Biopsy | 8 | 2021 | 540 | 0.310 |
Why?
|
| Pancreas | 4 | 2020 | 225 | 0.300 |
Why?
|
| Humans | 64 | 2021 | 68618 | 0.290 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2006 | 7 | 0.270 |
Why?
|
| Ileal Diseases | 1 | 2006 | 8 | 0.270 |
Why?
|
| Pathology | 2 | 2017 | 17 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 46 | 0.270 |
Why?
|
| Colonic Diseases | 1 | 2006 | 36 | 0.260 |
Why?
|
| Barrett Esophagus | 5 | 2005 | 57 | 0.260 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 75 | 0.260 |
Why?
|
| Gastric Antral Vascular Ectasia | 2 | 2018 | 6 | 0.260 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 129 | 0.250 |
Why?
|
| Precision Medicine | 2 | 2020 | 111 | 0.250 |
Why?
|
| Angiomatosis | 1 | 2004 | 5 | 0.240 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 22 | 0.240 |
Why?
|
| Male | 42 | 2021 | 37321 | 0.230 |
Why?
|
| Diagnosis, Differential | 8 | 2015 | 1140 | 0.230 |
Why?
|
| Colon | 4 | 2021 | 168 | 0.230 |
Why?
|
| Liver Diseases | 2 | 2021 | 193 | 0.230 |
Why?
|
| Hemangioma | 1 | 2004 | 51 | 0.230 |
Why?
|
| Aged | 28 | 2021 | 14862 | 0.220 |
Why?
|
| Adenoma | 2 | 2021 | 132 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2003 | 19 | 0.220 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 35 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 53 | 0.220 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 334 | 0.220 |
Why?
|
| Health Status Disparities | 3 | 2016 | 326 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 468 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 40 | 0.220 |
Why?
|
| Liver | 4 | 2015 | 1118 | 0.220 |
Why?
|
| Middle Aged | 31 | 2021 | 21147 | 0.210 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 91 | 0.200 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 185 | 0.190 |
Why?
|
| Immunity | 1 | 2021 | 67 | 0.190 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2020 | 14 | 0.190 |
Why?
|
| Liver Function Tests | 1 | 2021 | 114 | 0.190 |
Why?
|
| Lectins | 1 | 2020 | 81 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 9 | 0.180 |
Why?
|
| Rheumatic Diseases | 1 | 2021 | 35 | 0.180 |
Why?
|
| Neurofibroma | 1 | 2020 | 11 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 10 | 0.180 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 53 | 0.180 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 39 | 0.180 |
Why?
|
| Prognosis | 8 | 2021 | 2093 | 0.170 |
Why?
|
| Fatal Outcome | 3 | 2006 | 164 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2020 | 120 | 0.170 |
Why?
|
| Endosonography | 4 | 2010 | 177 | 0.170 |
Why?
|
| Adult | 27 | 2021 | 21403 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 163 | 0.160 |
Why?
|
| Esophageal Neoplasms | 4 | 2005 | 150 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 300 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2020 | 176 | 0.160 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2011 | 171 | 0.160 |
Why?
|
| Female | 34 | 2021 | 38074 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2015 | 87 | 0.150 |
Why?
|
| Immunohistochemistry | 7 | 2020 | 1174 | 0.150 |
Why?
|
| Helicobacter Infections | 4 | 1999 | 40 | 0.140 |
Why?
|
| Reperfusion Injury | 2 | 2014 | 320 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 18 | 0.140 |
Why?
|
| Helicobacter pylori | 4 | 1999 | 54 | 0.140 |
Why?
|
| Certification | 1 | 2017 | 66 | 0.140 |
Why?
|
| Intestine, Small | 1 | 1996 | 89 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 1996 | 219 | 0.130 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2020 | 34 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2015 | 103 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 114 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 2 | 2005 | 39 | 0.120 |
Why?
|
| Physician's Role | 1 | 1995 | 116 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2015 | 201 | 0.120 |
Why?
|
| Gastroenterology | 1 | 1995 | 98 | 0.110 |
Why?
|
| Hepatocytes | 1 | 2015 | 205 | 0.110 |
Why?
|
| Apoptosis | 3 | 2014 | 1641 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 1995 | 188 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2014 | 295 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2012 | 1173 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 102 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 369 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2010 | 76 | 0.110 |
Why?
|
| Pancreatectomy | 3 | 2010 | 129 | 0.110 |
Why?
|
| Inflammation | 2 | 2015 | 1030 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 657 | 0.100 |
Why?
|
| Biopsy, Needle | 4 | 2006 | 191 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2005 | 231 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 4 | 2005 | 78 | 0.090 |
Why?
|
| Telepathology | 1 | 2010 | 2 | 0.090 |
Why?
|
| Sensitivity and Specificity | 10 | 2007 | 1753 | 0.090 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2016 | 4848 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2011 | 239 | 0.090 |
Why?
|
| Tissue Adhesions | 1 | 2010 | 21 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 274 | 0.090 |
Why?
|
| Peritonitis | 1 | 2010 | 46 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 135 | 0.090 |
Why?
|
| Sarcoma, Myeloid | 1 | 2009 | 11 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2010 | 75 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 40 | 0.090 |
Why?
|
| Adolescent | 10 | 2017 | 8912 | 0.080 |
Why?
|
| Pancreaticojejunostomy | 2 | 2007 | 21 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2011 | 753 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2001 | 258 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 1851 | 0.080 |
Why?
|
| Gastroscopy | 3 | 2018 | 45 | 0.080 |
Why?
|
| Urease | 3 | 1999 | 5 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 536 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2006 | 2324 | 0.080 |
Why?
|
| Retrospective Studies | 10 | 2018 | 7277 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 168 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 163 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2006 | 1615 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 792 | 0.080 |
Why?
|
| Mice | 6 | 2020 | 8474 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2010 | 237 | 0.080 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2007 | 8 | 0.070 |
Why?
|
| Pancreatic Fistula | 1 | 2007 | 23 | 0.070 |
Why?
|
| Fatty Liver | 2 | 2004 | 97 | 0.070 |
Why?
|
| Reoperation | 2 | 2006 | 467 | 0.070 |
Why?
|
| Cholestasis | 1 | 2007 | 90 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 1056 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 104 | 0.070 |
Why?
|
| Colectomy | 2 | 2003 | 64 | 0.070 |
Why?
|
| Gastrointestinal Motility | 1 | 2006 | 52 | 0.070 |
Why?
|
| Laparotomy | 1 | 2006 | 65 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 511 | 0.070 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2005 | 15 | 0.070 |
Why?
|
| Hepatic Duct, Common | 1 | 2005 | 3 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 186 | 0.060 |
Why?
|
| Common Bile Duct | 1 | 2005 | 22 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 74 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1465 | 0.060 |
Why?
|
| Animals | 8 | 2020 | 20881 | 0.060 |
Why?
|
| Pancreatitis | 1 | 2007 | 279 | 0.060 |
Why?
|
| Manometry | 1 | 2006 | 276 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2007 | 1330 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 307 | 0.060 |
Why?
|
| Endotoxins | 1 | 2004 | 76 | 0.060 |
Why?
|
| Histocytochemistry | 2 | 2011 | 149 | 0.060 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2004 | 8 | 0.060 |
Why?
|
| Splenic Artery | 1 | 2004 | 16 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 658 | 0.060 |
Why?
|
| Portal Vein | 1 | 2004 | 46 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2004 | 20 | 0.060 |
Why?
|
| Algorithms | 3 | 2005 | 1196 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 18 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2003 | 13 | 0.060 |
Why?
|
| Hyperplasia | 2 | 2021 | 89 | 0.060 |
Why?
|
| Esophagus | 2 | 2005 | 303 | 0.060 |
Why?
|
| Prednisone | 1 | 2003 | 104 | 0.050 |
Why?
|
| Thrombosis | 1 | 2004 | 218 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 99 | 0.050 |
Why?
|
| Observer Variation | 4 | 2008 | 330 | 0.050 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 348 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2002 | 63 | 0.050 |
Why?
|
| Stomach | 2 | 1999 | 80 | 0.050 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2002 | 12 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 800 | 0.050 |
Why?
|
| Liver Transplantation | 2 | 2004 | 400 | 0.050 |
Why?
|
| Ampulla of Vater | 1 | 2002 | 34 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2002 | 19 | 0.050 |
Why?
|
| Registries | 2 | 2013 | 733 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2001 | 10 | 0.050 |
Why?
|
| Age Factors | 3 | 2013 | 1864 | 0.050 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 33 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2001 | 72 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2002 | 47 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2002 | 156 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 546 | 0.050 |
Why?
|
| Stents | 1 | 2005 | 657 | 0.050 |
Why?
|
| Glycosylation | 1 | 2021 | 185 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2021 | 38 | 0.050 |
Why?
|
| Gastric Mucosa | 2 | 2018 | 77 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 756 | 0.050 |
Why?
|
| Pyloric Antrum | 2 | 1997 | 10 | 0.050 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 299 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 213 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2007 | 3259 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 70 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 284 | 0.040 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 6 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 78 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 130 | 0.040 |
Why?
|
| Mediastinal Diseases | 1 | 1999 | 15 | 0.040 |
Why?
|
| Carcinoma | 1 | 2001 | 215 | 0.040 |
Why?
|
| Breath Tests | 1 | 1999 | 23 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 2223 | 0.040 |
Why?
|
| Serologic Tests | 1 | 1999 | 46 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2012 | 7029 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 304 | 0.040 |
Why?
|
| Neoplasms | 1 | 2010 | 1667 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1999 | 54 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 1213 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1999 | 77 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 1999 | 129 | 0.040 |
Why?
|
| Toxoplasmosis | 1 | 1997 | 13 | 0.040 |
Why?
|
| ras Proteins | 1 | 1999 | 102 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 100 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1997 | 26 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 85 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2017 | 10 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2017 | 24 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2013 | 714 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 1997 | 144 | 0.040 |
Why?
|
| Coloring Agents | 1 | 1997 | 66 | 0.040 |
Why?
|
| Glutens | 1 | 1996 | 10 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1996 | 85 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 1996 | 32 | 0.040 |
Why?
|
| Colitis | 1 | 1997 | 156 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 153 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1996 | 152 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 5717 | 0.030 |
Why?
|
| Incidence | 2 | 2013 | 1603 | 0.030 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2015 | 63 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 254 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2279 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2007 | 737 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 261 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 710 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 2358 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 87 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 137 | 0.030 |
Why?
|
| Risk Factors | 3 | 2010 | 5731 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2010 | 652 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2004 | 63 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 314 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2012 | 5 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 196 | 0.030 |
Why?
|
| Vinblastine | 1 | 2012 | 40 | 0.030 |
Why?
|
| Mitomycin | 1 | 2012 | 27 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2012 | 83 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1664 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 193 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 1752 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 770 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1692 | 0.020 |
Why?
|
| Cisplatin | 1 | 2012 | 192 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 866 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 31 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2017 | 596 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 170 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 579 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 93 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2010 | 24 | 0.020 |
Why?
|
| South Carolina | 2 | 2013 | 2752 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 78 | 0.020 |
Why?
|
| Enterococcus | 1 | 2010 | 29 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2009 | 6 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 35 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 53 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 63 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1046 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 2791 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 5 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 29 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 33 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 672 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 630 | 0.020 |
Why?
|
| Wound Healing | 1 | 2010 | 260 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 931 | 0.020 |
Why?
|
| Myelin and Lymphocyte-Associated Proteolipid Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2007 | 12 | 0.020 |
Why?
|
| Proteolipids | 1 | 2007 | 20 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2007 | 14 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2007 | 27 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 17 | 0.020 |
Why?
|
| Pain, Intractable | 1 | 2007 | 28 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2007 | 58 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 76 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 85 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 132 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 87 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2689 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Pancreatic Function Tests | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 199 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2006 | 82 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 145 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 248 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 66 | 0.020 |
Why?
|
| Morbidity | 1 | 2005 | 130 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.020 |
Why?
|
| Pruritus | 1 | 2005 | 35 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2002 | 2077 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.020 |
Why?
|
| Prospective Studies | 3 | 1997 | 3705 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2005 | 66 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2004 | 33 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 2005 | 79 | 0.020 |
Why?
|
| Consensus | 1 | 2005 | 211 | 0.020 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 370 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 275 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 159 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 700 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2004 | 195 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 453 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 492 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 431 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 780 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 65 | 0.010 |
Why?
|
| Celiac Artery | 1 | 2001 | 12 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 95 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 1266 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 306 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2001 | 60 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 2001 | 58 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 572 | 0.010 |
Why?
|
| Child | 2 | 2001 | 6405 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 1593 | 0.010 |
Why?
|
| Western World | 1 | 1999 | 1 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 110 | 0.010 |
Why?
|
| Japan | 1 | 1999 | 68 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2007 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1999 | 54 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1999 | 155 | 0.010 |
Why?
|
| Quality of Life | 1 | 2007 | 1515 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2001 | 458 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1999 | 489 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 305 | 0.010 |
Why?
|
| Logistic Models | 1 | 2001 | 1420 | 0.010 |
Why?
|
| Toxoplasma | 1 | 1997 | 23 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 1997 | 38 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1999 | 147 | 0.010 |
Why?
|
| Azure Stains | 1 | 1997 | 4 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 6 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1997 | 8 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 329 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1996 | 49 | 0.010 |
Why?
|
| Culture Media | 1 | 1996 | 155 | 0.010 |
Why?
|
| Prevalence | 1 | 1999 | 1619 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 4655 | 0.010 |
Why?
|